Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00021
|
|||||
| Drug Name |
Teniposide
|
|||||
| Synonyms |
4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside; Demethyl Epipodophyllotoxin Thenylidine Glucoside; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); PTG; Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; Teniposido; Teniposido [INN-Spanish]; Teniposidum; Teniposidum [INN-Latin]; VM 26; VM-26; VM-26 (TN); Vee M-26; Veham-Sandoz; Vehem; Vumon; Vumon (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11: 2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H32O13S
|
|||||
| Canonical SMILES |
COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O
|
|||||
| InChI |
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
|
|||||
| InChIKey |
NRUKOCRGYNPUPR-QBPJDGROSA-N
|
|||||
| CAS Number |
CAS 29767-20-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 656.7 | Topological Polar Surface Area | 189 | ||
| Heavy Atom Count | 46 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 14 | |||
| XLogP |
1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10300907
, 103589230
, 104253379
, 104645164
, 118046116
, 119526326
, 124757497
, 125164301
, 135692278
, 136178636
, 137001864
, 139137932
, 140852399
, 14912717
, 152035492
, 162037723
, 162174797
, 163620769
, 163686094
, 175267905
, 176484801
, 178103449
, 179116911
, 184811965
, 187072639
, 223384958
, 226396002
, 241050196
, 251887699
, 252220258
, 252390155
, 252401148
, 252451125
, 49965048
, 51063681
, 53788607
, 57405354
, 597750
, 7980753
, 99030090
, 99246079
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Teniposide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.